Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000
Debt
Debt-to-Equity Ratio0.79
Current Ratio1.40
Quick Ratio1.09
Price-To-Earnings
Trailing P/E Ratio24.66
Forward P/E Ratio19.30
P/E Growth1.7
Sales & Book Value
Annual Sales$22.87 billion
Price / Sales4.96
Cash Flow$5.7178 per share
Price / Cash18.46
Book Value$10.60 per share
Price / Book9.96
Profitability
EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins-0.60%
Return on Equity39.84%
Return on Assets12.05%
Miscellaneous
Employees40,655
Outstanding Shares1,073,990,000
Market Cap$109.82 billion
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co declared a quarterly dividend on Monday, June 18th. Stockholders of record on Wednesday, August 15th will be given a dividend of $0.5625 per share on Monday, September 10th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.13%. The ex-dividend date is Tuesday, August 14th. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) released its earnings results on Tuesday, July, 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.20. The company had revenue of $6.36 billion for the quarter, compared to analysts' expectations of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business's revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the business earned $1.11 earnings per share. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co issued an update on its FY18 earnings guidance on Tuesday, July, 24th. The company provided EPS guidance of $5.40-5.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.15. The company issued revenue guidance of $24-24.5 billion, compared to the consensus revenue estimate of $23.99 billion.
What price target have analysts set for LLY?
17 brokerages have issued 12-month price targets for Eli Lilly And Co's stock. Their predictions range from $86.00 to $115.00. On average, they anticipate Eli Lilly And Co's share price to reach $100.1333 in the next year. This suggests that the stock has a possible downside of 5.1%. View Analyst Price Targets for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eli Lilly And Co.
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which has underperformed lately, is a prudent decision in our view. The stock has outperformed the industry this year so far. However, competitive pressure on Lilly’s drugs is expected to rise this year. Challenges remain for the company in the form of upcoming loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Estimates have gone up slightly ahead of the Q2 earnings release. Lilly has a positive record of earnings surprises in recent quarters." (7/18/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reaffirm our OW rating and $100 12-month PT for LLY’s stock after hosting a conference call with two endocrinologists who disagree on the outcome for LLY’s REWIND trial. We have previously spoken with four physicians, two of which we hosted for this call. Trulicity is one of Lilly’s largest assets. FactSet consensus shows a five-year CAGR for Trulicity (2018-23) of ~9.9%. Based on our calls, most of the physicians expect a positive outcome for REWIND. This could increase Rxs by 20-30% or by multiples of current sales, which leads us to believe that significant upside remains in the drug, if the doctors are right. We expect top-line data by year-end 2018, and a presentation at ADA in June 2019." (7/17/2018)
Are investors shorting Eli Lilly And Co?
Eli Lilly And Co saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 14,985,331 shares, an increase of 26.7% from the July 13th total of 11,826,399 shares. Based on an average trading volume of 4,667,433 shares, the short-interest ratio is currently 3.2 days. Approximately 1.6% of the company's shares are sold short. View Eli Lilly And Co's Current Options Chain.
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
- Mr. Enrique A. Conterno, Sr. VP (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)
- Mr. Donald A. Zakrowski, Chief Accounting Officer and VP of Fin.
Has Eli Lilly And Co been receiving favorable news coverage?
Media stories about LLY stock have been trending positive on Saturday, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly And Co earned a daily sentiment score of 0.26 on Accern's scale. They also assigned media stories about the company an impact score of 45.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Eli Lilly And Co.
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by many different of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.24%), BlackRock Inc. (6.21%), Janus Henderson Group PLC (0.93%), Bank of New York Mellon Corp (0.88%), Massachusetts Financial Services Co. MA (0.68%) and Wells Fargo & Company MN (0.46%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which institutional investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Lilly Endowment Inc., American Century Companies Inc., Massachusetts Financial Services Co. MA, Bank of New York Mellon Corp, Bank of Montreal Can, Wells Fargo & Company MN and Retirement Systems of Alabama. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.
Which institutional investors are buying Eli Lilly And Co stock?
LLY stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Investec Asset Management LTD, Smith Asset Management Group LP, Unigestion Holding SA, FMR LLC, Janus Henderson Group PLC and DnB Asset Management AS. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $105.55.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $109.82 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
